Cooley advised Welsbach Technology Metals Acquisition Corp. on the deal. Welsbach Technology Metals Acquisition Corp., a publicly traded special purpose acquisition company, announced its definitive merger agreement...
Welsbach Technology Metals Acquisition Corp.’s Merger with WaveTech Group
Vaxcyte’s $690 Million Public Offering
Cooley advised Vaxcyte, while Latham & Watkins represented the underwriters on the offering. Vaxcyte, a clinical-stage vaccine innovation company, announced its underwritten public offering of common stock and...
Levvels’ Introduction of Momentica
Cooley advised LEVVELS on the deal. LEVVELS announced the introduction of MOMENTICA, a flagship platform for fan-artist engagement built on sustainable blockchain technology. LEVVELS is a joint...
Traive’s $10 Million Pre-Series B Investment Round
Koley and Jessen advised Traive, while Veirano Advogados and Cooley advised BASF VC on the deal. Traive closed its Pre-Series B investment round of US$10 million led...
European Biotech Acquisition’s $200 Million Combination With Oculis
Davis Polk advised European Biotech Acquisition Corp. on the deal while Cooley and Vischer represented Oculis. European Biotech Acquisition Corp. (EBAC), a SPAC, signed its $200 million...
Glasswing Ventures’ $158 Million Fundraising
Cooley advised Glasswing Ventures on the deal. Glasswing Ventures, an early-stage venture capital firm, announced its oversubscribed $158 million Fund II. Founded in 2016 and headquartered in...
Razor’s Edge’s $340 Million Third Investment Fund
Cooley advised Razor’s Edge on the deal. Razor’s Edge, a top national security-focused technology investor, announced its oversubscribed $340 million third investment fund. Significantly exceeding Razor’s Edge’s...
Lerer Hippeau’s $230 Million Formation of Two New Funds
Cooley advised Lerer Hippeau on the deal. Lerer Hippeau, an early-stage venture capital firm, announced the formation of two new funds – LH Seed VIII and LH...
Immunovant’s $75 Million Common Stock Offering
Cooley represented Immunovant, while Latham & Watkins represented the underwriters in the offering. Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company committed to enabling normal lives for...
Pigment’s $65 Million Series B Financing Round
Jones Day advised Pigment on the deal. Viguié Schmidt & Associés and Cooley advised Meritech Capital and IVP. Pigment, a French startup developing a business planning...
Innervace’s $40 Million Series A Financing
Troutman Pepper advised Innervace on the deal. Innervace, a regenerative medicine company developing the first implantable biofabricated neural pathway to restore brain circuitry, announced its $40...
Pie Insurance’s $315 Million Series D Funding Round
Cooley advised Pie Insurance, Kirkland & Ellis advised Centerbridge Partners, and Sullivan & Cromwell advised Allianz X on the deal. Pie Insurance (Pie) executed a $315 million Series...